Chronic rhinitis

MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )--Aerin Medical, Inc., (“Aerin” or “the Company”) a high-growth medical device company focused on expanding access to meaningful relief for millions of patients suffering from chronic ENT conditions, today announced the successful completion of two significant financial transactions. These transactions position the Company to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin's major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital. “This additional funding significantly strengthens our financial position, supporting continued commercial expansion, along with investments in significant R&D and leading clinical evidence-generation that have been signatures of Aerin’s progress,” said Matt Brokaw, CEO of Aerin Medical. “The confidence demonstrated by our investors reflects the momentum we’ve built in bringing meaningful innovations to otolaryngologists and their patients.” “We are proud to support Aerin and the significant advancements they continue to make in ENT care,” said Karen Long, Sr. Managing Director at KCK Group and Chairman of Aerin Medical Board of Directors. “This is an exciting time for Aerin as they continue to deepen their penetration in the market for large unmet medical needs in nasal obstruction and chronic rhinitis. Our focus will be on ensuring access to these critical technologies for all patients who would benefit.” “We are excited to provide financing to Aerin as they continue to expand their footprint in ENT,” said Kris Talgo, Principal in the at Ares Credit Group. “The strength of Aerin’s management team and their strong track record of well-designed, well-studied solutions is a testament to their dedication and expertise. We look forward to supporting them in their next phase of growth.” About Aerin Medical Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer ® for nasal airway obstruction and RhinAer ® for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 150,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook , X , Instagram , LinkedIn and YouTube . Forward Looking Statements In addition to background and historical information, this press release contains “forward-looking statements” based on Aerin ’s current expectations, forecasts and beliefs, including among other things, the statements related to commercial strategy, execution, and expansion, operational performance, and growth, above. These forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Actual outcomes and results could differ materially due to a number of factors. Forward -looking statements contained in this announcement are based on information available to Aerin as of the date hereof. Aerin undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Aerin’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors and/or readers are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about Aerin.

Recent study confirms safety and efficacy of NEUROMARK® for chronic rhinitis GALWAY, Ireland , June 6, 2024 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the publication of positive 12-month results from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology. This study demonstrates that treatment with Neurent Medical's radiofrequency (RF) ablation device, the NEUROMARK® system, is safe and resulted in durable, significant improvement in rhinitis symptoms and quality of life through 12-month follow-up. Key Findings: Continue Reading Dr. Reh added, "The CLARITY study results provide compelling evidence of sustained symptom relief for patients." Post this Symptom Reduction: All 5 Visual Analog Scale Nasal Symptom Score (VAS NSS) items demonstrated significant improvement (p<.0001) over baseline at all 3 time points (6, 9, and 12 months). The reflective Total Nasal Symptom Score (rTNSS) improved from baseline at all 3 time points (p<.0001). A total of 91% of participants achieved the minimum clinically important difference (MCID) of a reduction from baseline of ≥1 point for the rTNSS at 12 months. Clinical Safety: The procedure showed a consistent safety profile, with no serious adverse events related to the RF ablation device observed throughout the study. Quality of Life Improvement: The total mean mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) significantly improved from baseline at all 3 time points (p<.0001). A total of 86% of participants achieved the MCID of a reduction from baseline of ≥0.4 points for the mini RQLQ at 12 months. Brian Shields, CEO of Neurent Medical, overviewed the significance of these findings, "This publication further validates the efficacy of our algorithm-driven patented technology for the treatment of chronic rhinitis. The publication of our device's long-term efficacy and safety data in Laryngoscope Investigative Otolaryngology reaffirms our commitment to building strong clinical evidence to support the continued adoption of our innovative solutions that significantly improve outcomes and patient quality of life." Lead investigator Dr. Douglas D. Reh added, "The CLARITY study results provide compelling evidence of sustained symptom relief and enhanced quality of life for patients suffering from chronic rhinitis. This important research better elucidates the neurovascular component of chronic rhinitis and underscores the potential of Neurent Medical's RF ablation device as a transformative treatment option with durable relief." The publication of this study further represents a noteworthy advancement in the field of sinonasal treatment options. The long-term data presented in the CLARITY study not only informs healthcare providers' treatment decisions but also paves the way for future potential payor coverage considerations. As Neurent Medical continues to innovate, the company remains committed to improving the standard of care for chronic rhinitis patients nationwide. The full publication may be accessed online here: . About the NEUROMARK ® System The NEUROMARK ® System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radio frequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis. The system is engineered to gently apply controlled low-power Radio Frequency (RF) energy to target regions of the nasal cavity to disrupt the parasympathetic nerve signals in order to reduce the inflammatory response, thereby reducing core symptoms such as congestion and rhinorrhea. About Neurent Medical Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit . SOURCE Neurent Medical

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer. The company is developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant. Septal deviation is one of the most common causes of nasal airway obstruction (NAO), a condition that makes it difficult to breathe through the nose. 1 Despite advancements in techniques, treatments and technologies in the otolaryngology (ENT) field broadly, NSD correction has remained stagnant for years. Treatment options for symptomatic NSD have been limited to either over-the-counter medications to alleviate symptoms or invasive surgical techniques to address the structural issues that cause these symptoms. Traditional septoplasty or septorhinoplasty are the most common surgical treatment options for NSD. Septoplasty can require significant time away from work, with approximately 40% of patients requiring two or more weeks off for recovery. 2 “ Our team is partnering with leading ENT advisors and industry veterans to develop minimally invasive solutions that provide strong outcomes and a better experience for their patients,” said Bishop. “ I’m proud to join this team of innovators who are working to add treatment options to physicians’ toolkits to help them continue supporting their patients.” Bishop joins Spirair with two decades of commercial leadership experience across the medical, surgical and aesthetic industries. He has a proven track record for successfully launching disruptive technologies and establishing new markets, playing a key role in developing high-growth companies like Revelle Aesthetics, Revance Therapeutics, and Access Closure. Bishop also led sales and marketing at Arrinex – the company that developed ClariFix ® , an ENT technology for chronic rhinitis – prior to its acquisition by Stryker in 2019. Spirair got its start in the Stanford Biodesign Innovation Fellowship, a program that equips aspiring innovators with a proven, repeatable process to identify important health-related needs, invent novel health technologies to address them, and prepare to implement those products into patient care. Founders James Kintzing, Ph.D. and Brandon McCutcheon, M.D. were co-fellows in the program and identified an opportunity in the ENT space when they discovered the unmet need for a minimally invasive nasal septal deviation correction therapy to help address nasal airway obstruction. “ As an alumna of the Stanford Biodesign Innovation Fellowship myself, I’ve seen firsthand how this program successfully supports groundbreaking ideas in healthcare technology – and Spirair is a shining example of this innovation,” said Kate Garrett, managing partner at Sonder Capital, assistant director of the Stanford Biodesign Innovation Fellowship and chair of Spirair’s board of directors. “ Benjamin Bishop has an outstanding track record as a commercial leader and I’m thrilled to welcome him to Spirair as its chief executive officer as we begin this exciting next stage of growth.” Spirair’s nasal septal deviation therapy is currently being investigated as part of two IRB-approved nonsignificant risk (NSR) U.S. clinical trials. The company expects to begin a Series B fundraising round and initiate its commercialization efforts in 2024. 1 Clark DW, Del Signore AG, Raithatha R, Senior BA. Nasal airway obstruction: Prevalence and anatomic contributors. Ear Nose Throat J. 2018 Jun;97(6):173-176. doi: 10.1177/014556131809700615. PMID: 30036414. 2 Chidambaram A, et al. Anticipated absence from work ('sick leave') following routine ENT surgery: are we giving the correct advice? A postal questionnaire survey. Clin Otolaryngol Allied Sci. 2001 Apr;26(2):104-8. doi: 10.1046/j.1365-2273.2001.00433.x. PMID: 11309049. About Spirair Spirair is an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients by providing strong outcomes and a better patient experience. Spirair is committed to developing new therapies that can easily integrate in any ENT’s treatment algorithms so they can help more of their patients breathe better. Its first product is a novel minimally invasive option for symptomatic NSD that supports and straightens minor deviations in the septal cartilage and can be conveniently and safely performed under local anesthesia in any site of service as part of standard septoplasty techniques. The company got its start through the Stanford Biodesign Innovation Fellowship, a program that equips aspiring innovators with a proven, repeatable process to identify important health-related needs, invent novel health technologies to address them, and prepare to implement those products into patient care.